Noriyuki Shinagawa

Noriyuki Shinagawa

Auto-generated profile, based on publicly available information

Noriyuki Shinagawa

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KMKatherine E. Miller
Katherine E. Miller
ARAdithe C. Rivaldi
Adithe C. Rivaldi
NSNoriyuki Shinagawa
Noriyuki Shinagawa
SSSahib Sran
Sahib Sran
JNJason B. Navarro
Jason B. Navarro
TBTracy A. Bedrosian
Tracy A. Bedrosian

4 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JLJi-Hoon Lee
Ji-Hoon Lee
JLJulia LeCher
Julia LeCher
EPEric Parigoris
Eric Parigoris
NSNoriyuki Shinagawa
Noriyuki Shinagawa
JSJason Sentosa
Jason Sentosa
STShuichi Takayama
Shuichi Takayama
While breakthroughs with organoids have emerged as next-generation in vitro tools, standardization for drug discovery remains a challenge. This work introduces human airway organoids with reversed biopolarity (AORBs), cultured and analyzed in a high-throughput, single-organoid-per-well format, enabling milestones towards standardization. AORBs exhibit a spatio-temporally stable apical-out morphology, facilitating high-yield direct intact-organoid virus infection. Single-cell RNA sequencing and immunohistochemistry confirm the physiologically relevant recapitulation of differentiated human airway epithelia. The cellular tropism of five severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains along with host response differences between Delta, Washington, and Omicron variants, as observed in transcriptomic profiles, also suggest clinical relevance. Dose-response analysis of three well-studied SARS-CoV-2 antiviral compounds (remdesivir, bemnifosbuvir, and nirmatrelvir) demonstrates that AORBs efficiently predict human efficacy, comparable to gold-standard air-liquid interface cultures, but with higher throughput (∼10-fold) and fewer cells (∼100-fold). This combination of throughput and relevance allows AORBs to robustly detect false negative results in efficacy, preventing irretrievable loss of promising lead compounds. While this work leverages the SARS-CoV-2 study as a proof-of-concept application, the standardization capacity of AORB holds broader implications in line with regulatory efforts to push alternatives to animal studies.